NR1H4 and metabolic dysfunction-associated steatotic liver disease: Obeticholic acid, a semi-synthetic FXR agonist, is one of many promising candidates for the treatment of NAFLD, although there are some concerns over the cardiovascular effects of the drug [82,86].